{
    "Trade/Device Name(s)": [
        "Access OV Monitor"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K240479",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023597"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTK"
    ],
    "Summary Letter Date": "May 10, 2024",
    "Summary Letter Received Date": "February 20, 2024",
    "Submission Date": "May 01, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "CA 125 antigen"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Paramagnetic particle chemiluminescent immunoassay",
        "Sandwich immunoenzymatic assay",
        "Automated"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent",
        "Buffer",
        "Analyzer"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access OV Monitor assay for quantitative CA 125 antigen determination on the DxI 9000 analyzer in management of ovarian cancer",
    "Indications for Use Summary": "Quantitative measurement of CA 125 antigen in human serum and plasma to aid in the management of ovarian cancer patients; serial testing used in conjunction with other clinical methods for monitoring ovarian cancer",
    "fda_folder": "Immunology"
}